The Effect of Continuous Glucose Monitoring in Surgical Patients with Diabetes.
Launched by CHRISTIAN S. MEYHOFF · Mar 14, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a device called the Dexcom G7, which continuously monitors blood sugar levels, in surgical patients who have diabetes. The main goal is to find out if using this device can help keep blood sugar levels more stable compared to the usual method of checking blood sugar with a finger prick. Patients in the trial will wear the CGM device during their hospital stay, and it will alert nurses if their blood sugar levels go too high or too low.
To participate, individuals must have diabetes and be scheduled for certain surgeries that last longer than 45 minutes, requiring at least one night in the hospital afterward. This trial is open to all genders and is currently looking for participants aged 65 to 74. It’s important to note that some people may not be eligible if they have certain skin conditions, allergies, or medical devices like pacemakers. Throughout the study, all patients will receive standard diabetes care, and the monitoring device will be worn for up to 10 days or until they leave the hospital.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Medical history with diabetes mellitus (DM1 or DM2 (insulin-dependent and non-insulin-dependent) requiring antidiabetic drug(s)
- • Acute or elective abdominal, orthopaedic, urological, or vascular surgery with estimated duration of surgery \>45 minutes
- • Expected stay for at least one night in the hospital postoperatively
- Exclusion Criteria:
- • Local skin symptoms including infection at the posterior aspect of the upper arm that does not allow the sensor to be placed on an unaffected skin area
- • Known allergy to the equipment plaster
- • Known pregnancy
- • Patients with pacemaker or implantable cardioverter defibrillator (ICD) device
- • Previous or currently scheduled for pancreatectomy (complete or partial)
- • Patients receiving hydroxyurea (these drugs may interfere with CGM readings)
About Christian S. Meyhoff
Christian S. Meyhoff is a dedicated clinical trial sponsor with extensive experience in the design, implementation, and management of innovative research studies. Committed to advancing medical knowledge and improving patient outcomes, he focuses on rigorous scientific methodologies and ethical standards throughout the clinical research process. His expertise spans various therapeutic areas, and he actively collaborates with healthcare professionals and research institutions to facilitate the efficient conduct of trials. By fostering a culture of transparency and accountability, Christian S. Meyhoff aims to contribute significantly to the development of safe and effective therapies for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Køge, , Denmark
Copenhagen, The Capital Region Of Denmark, Denmark
Copenhagen, The Capital Region Of Denmark, Denmark
Patients applied
Trial Officials
Christian S Meyhoff, MD, PhD
Study Director
University Hospital Bispebjerg and Frederiksberg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported